The Drug Regulatory Authority of Pakistan has formally requested the Pakistan Telecommunication Authority to block access to a website allegedly involved in the sale of unauthorised and unregistered therapeutic products, in a move reflecting intensifying oversight of online health markets.

In an official communication, DRAP cited a public complaint received through its online portal, identifying the website herbaltelestore.pk as being engaged in the unlawful sale of therapeutic goods that have not been approved or registered with the regulator.

According to the authority, such activity violates multiple provisions of Pakistan’s drug regulatory framework, including clauses under the DRAP Act, 2012 and the Drugs Act, 1976, making it a punishable offence. Supporting evidence, including screenshots of the website, has been submitted to the telecom regulator for further action.

Public Health Risks Highlighted

DRAP warned that the online availability of unregistered therapeutic products poses a “serious potential risk” to public health, as such items may bypass safety, quality and efficacy checks required under Pakistani law.

Officials noted that the rise of digital platforms has enabled the proliferation of unregulated health products, often marketed directly to consumers without medical supervision or regulatory approval.

Call for Immediate Action

The authority has urged PTA to take necessary steps under applicable legal and regulatory provisions to block access to the identified website, and to inform DRAP once action has been completed.

The request follows ongoing coordination between the two regulators aimed at curbing unlawful online activities related to therapeutic goods, as Pakistan’s digital commerce landscape continues to expand.

Wider Crackdown Expected

Regulatory officials that further actions may follow as DRAP continues to monitor complaints and track online platforms suspected of violating drug laws.

The development underscores growing concerns within the health sector over the unchecked sale of medicines and therapeutic products online — an issue authorities say requires swift enforcement to protect consumers.